Previously located in Florida and now moved to Mountain View, CA, and having a new url, Specific Technologies has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid identification of microorganisms. The first commercial application applies this fundamental new platform to the detection and characterization of microorganisms causing blood stream infection, and to the rapid and low cost phenotypic determination of their antibiotic susceptibility. Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is among the most expensive condition treated. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies can require days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific’s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. The firm's unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. - streamlining lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific personnel have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.
